Catheter Related Bloodstream Infection (CRBSI) Market
Catheter-Related Bloodstream Infection Market by Drug Class, Pathogens, Source of Infection, Route of Administration, Distribution Channel Region | Forecast 2023 to 2033
Market Insights on Catheter Related Bloodstream Infection (CRBSI) covering sales outlook, demand forecast and up-to-date key trends
Catheter-Related Bloodstream Infection Market Snapshot (2023 to 2033)
The global catheter-related bloodstream infection market is expected to garner a market value of US$ 44.67 Billion in 2023 and is expected to accumulate a market value of US$ 80 Billion by registering a CAGR of 6% in the forecast period 2023 to 2033. The growth of the catheter-related bloodstream infection market can be attributed to an increase in the number of people facing urinary infections. The market for catheter-related bloodstream infection registered a CAGR of 4.5% in the historical period 2017 to 2022
The diagnosis of catheter-related bloodstream infections remains a major challenge. Fever and chills that are often associated with catheter-related bloodstream infections are not specific. Furthermore, local catheter inflammation and phlebitis could exist in the absence of catheter-related bloodstream infection or even a local infection, as has been reported with peripherally inserted central catheters. This, in turn, is creating a positive opportunity for the catheter-related bloodstream infection market.
|
Report Attribute |
Details |
|
Estimated Base Year Value (2021) |
US$ 42.14 Billion |
|
Expected Market Value (2023) |
US$ 44.67 Billion |
|
Anticipated Forecast Value (2033) |
US$ 80 Billion |
|
Projected Growth Rate (2023 to 2033) |
6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2017 to 2022 Catheter-Related Bloodstream Infection Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for catheter-related bloodstream infection reflected a value of 20% during the historical period, 2017 to 2022.
The number of people being diagnosed with catheter-related bloodstream infections is increasing owing to the treatments they undergo through. This has led to an increase in blood-related communicable diseases. The diagnosis along with the absence of exact treatment for catheter-related bloodstream infection is spurring the research and development for the treatment for the infection. Moreover, an increase in technological advancement is expected to propel the treatment for catheter-related bloodstream infections.
Thus, the market for catheter-related bloodstream infections is expected to register a CAGR of 29% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Catheter-Related Bloodstream Infection Market?
Risk in the prevalence of bloodstreams infection driving the growth of the catheter-related bloodstream infection market
The 'gold standard' for the diagnosis of catheter-related bloodstream infection is the combination of positive blood culture with the same organism isolated from the catheter. However, a major diagnostic problem is that traditional methods of catheter culture necessitate the removal of the central venous catheters (CVC), whereby the line tip is either rolled on an agar plate or placed in a nutrient broth.
The rise in the prevalence of bloodstream infection is projected to drive the global market. An article published in Continuing Education in Anaesthesia, Critical Care & Pain stated that catheter-related bloodstream infections occur in ~3% of catheterizations; however, the incidence could be as high as 16%. Serious effects associated with inaccurate diagnoses, such as procedural complications, lead to an increase in morbidity and mortality. Hence, it is essential to make an accurate diagnosis of catheter-related bloodstream infections.
Health-care acquired infections spurring the growth of the catheter-related bloodstream infection market
Hospital-acquired infection increases the risk of CRBSI. According to the International Journal of Critical Illness and Injury Science, CRBSI accounts for 10% to 20% of hospital-acquired infections in the UK
Governments in developing countries are making significant investments toward the modernization of healthcare infrastructure, which is likely to increase access to healthcare. Moreover, healthcare-acquired infection is a major issue in developing countries. Hence, an increase in demand for the products owing to a surge in patient population presents significant opportunities in the global market.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Catheter-Related Bloodstream Infection Market?
Undiagnosable reasons for infection derailing the progress of the market
The major problem faced by catheter-related bloodstream infection is the increasing number of patients being diagnosed with catheter-related bloodstream infection problems whereas on the other hand unavailability of exact treatment is derailing the progress of the market. In most cases, the reason for the infection is undiagnosed. This, in turn, is hampering the growth of the overall market.
Region-Wise Insights
Well, Established Healthcare Infrastructure Creating Lucrative Opportunities for the Catheter-Related Blood Infection Market in North America?
Availability of various treatments fueling the growth of the catheter-related blood infection market in North America
North America is projected to account for a major share of the global catheter-related bloodstream infections market during the forecast period due to well-established healthcare infrastructure. Technological advancements in the healthcare sector to treat blood-related infections are playing a key role in shaping the overall market.
The increasing number of people facing catheter-related blood infections in the USA and Canada, especially the geriatric population is contributing to the market in North America. In addition, the availability of various treatments for catheter-related blood infections is fueling the growth of the market. Thus, North America is expected to possess a 35% market share for the catheter-related bloodstream infection market in 2023.
Growing Prevalence of hospital-acquired infections Contributing to Catheter-Related Blood Infections in Asia Pacific?
Diagnosis-specific treatments shaping the market for catheter-related blood infection in Asia Pacific
The catheter-related bloodstream infections market in Asia Pacific is expected to grow at a rapid pace during the forecast period owing to the rise in the prevalence of hospital-acquired infections. According to the World Health Organization Department of Communicable Disease, the risk of healthcare-associated infection is 2 to 20 times higher in developing countries than in developed countries.
The presence of a wider patient pool that consists of nearly all age groups is another factor contributing to the growth of the market in Asia Pacific. Countries such as China, India, and Japan are focusing on using treatments that are age and diagnosis-specific. This, in turn, is shaping the market for catheter-related blood infection market. Thus, Asia Pacific is expected to possess a 30% market share for the catheter-related bloodstream infection market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Anti-microbial Agents Contributing to Catheter-Related Bloodstreams Infections?
Antimicrobial agents causing urinary tract infections in patients
By drug class, the catheter-related bloodstream infection market is segmented into Drug Class (Non-antibiotic, Anti-infective, Antimicrobial),
The presence of different types of antimicrobial agents which inhibit the colonization of the catheters with pathogenic microbes and prevent CAUTIs are causing bloodstream infections. Although antimicrobial catheters have numerous qualities such as releasing antimicrobial agents, modifying the surface of catheters, contact killing, disrupting the biofilms formed on catheters, and using bacterial biofilms to prevent pathogen colonization. Despite these attributes, the rate of causing urinary tract infections by antimicrobial catheters is still high.
Thus, owing to the aforementioned reasons, antimicrobial catheters are expected to possess a 35% market share for catheter-related bloodstream infections in 2023.
The convenience of Treatments and Availability of Medication Favoring Growth of the Catheter-Related Bloodstream Infection Market?
Multiple options for treating catheter-related bloodstream infections favor the growth of hospital pharmacies
By distribution channel, the catheter-related bloodstream infection market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Most patients have exhibited a preference towards hospital pharmacies owing to the convenience of treatment and availability of medicines offered at hospitals. Moreover, proper diagnosis and multiple options for treating catheter-related bloodstream infections are increasing visits to hospital pharmacies by patients.
Thus, hospital pharmacies are expected to possess a 40% market share of the catheter-related bloodstream infections market in 2022.
Market Competition
The global catheter-related bloodstream infections market is highly consolidated due to the presence of a small number of key players. These players hold a major share in their respective regions.
Demand for catheter-related bloodstream infections products has increased in emerging as well as developed markets owing to the rise in the prevalence of bloodstream infections. Growth strategies and focus on research & development by key players are the factors likely to drive the global catheter-related bloodstream infections market. For instance,
Key players in catheter-related bloodstream infection are Xellia Pharmaceuticals Ltd, Pfizer, Glenmark Pharmaceuticals Ltd, Fresenius Medical Care, CorMedix, TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca Pharma India Ltd, Merck Sharp & Dohme Corp
- In December 2022, CorMedix presented highlights of research that was conducted by integrating multiple clinical and claims databases that track a large cohort of kidney failure patients on hemodialysis (HD) with central venous catheters (CVCs). Thus, the company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases that are caused due to catheter-related bloodstream infections.
- Pfizer, a key player in catheter-related bloodstream infections is focusing on undertaking research and developing medication depending on the source of infection for treating bloodstream infections. Through this, the company is planning to create different medications for catheter-related infections.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 44.67 Billion |
|
Market Value in 2033 |
US$ 80 Billion |
|
Growth Rate |
CAGR of 6% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2017 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Catheter-Related Bloodstream Infection Market Industry Survey
Drug Class:
- Non-antibiotic
- Anti-infective
- Antimicrobial
Pathogens:
- Contaminated Catheter Hub
- Contaminated Infusate
- Skin Insertion
- Hematogenous
Source of Infection:
- Aureus
- Aeruginsa
- CONS
- Baumanii
- Coli
- Pnemoniae
- Candida sp
Route of Administration:
- Oral
- Intravenous
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia & Pacific
- Middle East & Africa
Frequently Asked Questions
At what rate did the catheter-related bloodstream Infection market flourish from 2017 to 2022?
From 2017 to 2022, the catheter-related bloodstream Infection market grew at a CAGR of 4.5%
What will be the growth rate of the global catheter-related bloodstream Infection market during the forecast period?
The global catheter-related bloodstream Infection market is expected to grow with a 6% CAGR from 2023 to 2033.
What will be the projected market size of the catheter-related bloodstream Infection market by 2033?
As of 2033, the catheter-related bloodstream Infection market is expected to reach US$ 80 Billion
Which distribution channel is expected to dominate the global catheter-related bloodstream Infection market during 2023?
Hospital pharmacies are expected to possess a 40% market share in the catheter-related bloodstream infections market in 2023.
Which type drug class is expected to dominate the global catheter-related bloodstream Infection market during 2023?
Antimicrobial catheters are expected to possess a 35% market share for catheter-related bloodstream infections in 2023.
How is the North America catheter-related bloodstream Infection market projected to grow in 2023?
North America is expected to possess a 35% market share for the catheter-related bloodstream infection market in 2023.
How is the Asia Pacific catheter-related bloodstream Infection market projected to grow in 2023?
Asia Pacific is expected to possess a 30% market share for the catheter-related bloodstream infection market in 2023.
Table of Content
1. Executive Summary | Catheter-Related Bloodstream Infection Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Non-antibiotic 5.3.2. Anti-infective 5.3.3. Antimicrobial 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Pathogenesis 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Pathogenesis, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Pathogenesis, 2023 to 2033 6.3.1. Contaminated Catheter Hub 6.3.2. Contaminated Infusate 6.3.3. Skin Insertion 6.3.4. Hematogenous 6.4. Y-o-Y Growth Trend Analysis By Pathogenesis, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Pathogenesis, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Source of Infection 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Source of Infection, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Source of Infection, 2023 to 2033 7.3.1. Aureus 7.3.2. Aeruginsa 7.3.3. CONS 7.3.4. Baumanii 7.3.5. Coli 7.3.6. Pnemoniae 7.3.7. Candida sp. 7.4. Y-o-Y Growth Trend Analysis By Source of Infection, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Source of Infection, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 8.3.1. Oral 8.3.2. Intravenous 8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Online Pharmacies 9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. South Asia & Pacific 10.3.5. East Asia 10.3.6. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. United States of America 11.2.1.2. Canada 11.2.2. By Drug Class 11.2.3. By Pathogenesis 11.2.4. By Source of Infection 11.2.5. By Route of Administration 11.2.6. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Pathogenesis 11.3.4. By Source of Infection 11.3.5. By Route of Administration 11.3.6. By Distribution Channel 11.4. Key Takeaways 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Brazil 12.2.1.2. Mexico 12.2.1.3. Rest of Latin America 12.2.2. By Drug Class 12.2.3. By Pathogenesis 12.2.4. By Source of Infection 12.2.5. By Route of Administration 12.2.6. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Pathogenesis 12.3.4. By Source of Infection 12.3.5. By Route of Administration 12.3.6. By Distribution Channel 12.4. Key Takeaways 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United Kingdom 13.2.1.3. France 13.2.1.4. Spain 13.2.1.5. Italy 13.2.1.6. Rest of Europe 13.2.2. By Drug Class 13.2.3. By Pathogenesis 13.2.4. By Source of Infection 13.2.5. By Route of Administration 13.2.6. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Pathogenesis 13.3.4. By Source of Infection 13.3.5. By Route of Administration 13.3.6. By Distribution Channel 13.4. Key Takeaways 14. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Malaysia 14.2.1.3. Singapore 14.2.1.4. Thailand 14.2.1.5. Australia 14.2.1.6. New Zealand 14.2.1.7. Rest of South Asia & Pacific 14.2.2. By Drug Class 14.2.3. By Pathogenesis 14.2.4. By Source of Infection 14.2.5. By Route of Administration 14.2.6. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Pathogenesis 14.3.4. By Source of Infection 14.3.5. By Route of Administration 14.3.6. By Distribution Channel 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Drug Class 15.2.3. By Pathogenesis 15.2.4. By Source of Infection 15.2.5. By Route of Administration 15.2.6. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Pathogenesis 15.3.4. By Source of Infection 15.3.5. By Route of Administration 15.3.6. By Distribution Channel 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Pathogenesis 16.2.4. By Source of Infection 16.2.5. By Route of Administration 16.2.6. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Pathogenesis 16.3.4. By Source of Infection 16.3.5. By Route of Administration 16.3.6. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. United States of America 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Class 17.1.2.2. By Pathogenesis 17.1.2.3. By Source of Infection 17.1.2.4. By Route of Administration 17.1.2.5. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Class 17.2.2.2. By Pathogenesis 17.2.2.3. By Source of Infection 17.2.2.4. By Route of Administration 17.2.2.5. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Class 17.3.2.2. By Pathogenesis 17.3.2.3. By Source of Infection 17.3.2.4. By Route of Administration 17.3.2.5. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Class 17.4.2.2. By Pathogenesis 17.4.2.3. By Source of Infection 17.4.2.4. By Route of Administration 17.4.2.5. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Class 17.5.2.2. By Pathogenesis 17.5.2.3. By Source of Infection 17.5.2.4. By Route of Administration 17.5.2.5. By Distribution Channel 17.6. United Kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Class 17.6.2.2. By Pathogenesis 17.6.2.3. By Source of Infection 17.6.2.4. By Route of Administration 17.6.2.5. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Class 17.7.2.2. By Pathogenesis 17.7.2.3. By Source of Infection 17.7.2.4. By Route of Administration 17.7.2.5. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Class 17.8.2.2. By Pathogenesis 17.8.2.3. By Source of Infection 17.8.2.4. By Route of Administration 17.8.2.5. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Class 17.9.2.2. By Pathogenesis 17.9.2.3. By Source of Infection 17.9.2.4. By Route of Administration 17.9.2.5. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Class 17.10.2.2. By Pathogenesis 17.10.2.3. By Source of Infection 17.10.2.4. By Route of Administration 17.10.2.5. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Class 17.11.2.2. By Pathogenesis 17.11.2.3. By Source of Infection 17.11.2.4. By Route of Administration 17.11.2.5. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Class 17.12.2.2. By Pathogenesis 17.12.2.3. By Source of Infection 17.12.2.4. By Route of Administration 17.12.2.5. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Class 17.13.2.2. By Pathogenesis 17.13.2.3. By Source of Infection 17.13.2.4. By Route of Administration 17.13.2.5. By Distribution Channel 17.14. Australia 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Class 17.14.2.2. By Pathogenesis 17.14.2.3. By Source of Infection 17.14.2.4. By Route of Administration 17.14.2.5. By Distribution Channel 17.15. New Zealand 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Class 17.15.2.2. By Pathogenesis 17.15.2.3. By Source of Infection 17.15.2.4. By Route of Administration 17.15.2.5. By Distribution Channel 17.16. China 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Class 17.16.2.2. By Pathogenesis 17.16.2.3. By Source of Infection 17.16.2.4. By Route of Administration 17.16.2.5. By Distribution Channel 17.17. Japan 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Class 17.17.2.2. By Pathogenesis 17.17.2.3. By Source of Infection 17.17.2.4. By Route of Administration 17.17.2.5. By Distribution Channel 17.18. South Korea 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Class 17.18.2.2. By Pathogenesis 17.18.2.3. By Source of Infection 17.18.2.4. By Route of Administration 17.18.2.5. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Class 17.19.2.2. By Pathogenesis 17.19.2.3. By Source of Infection 17.19.2.4. By Route of Administration 17.19.2.5. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Class 17.20.2.2. By Pathogenesis 17.20.2.3. By Source of Infection 17.20.2.4. By Route of Administration 17.20.2.5. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Class 17.21.2.2. By Pathogenesis 17.21.2.3. By Source of Infection 17.21.2.4. By Route of Administration 17.21.2.5. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Pathogenesis 18.3.4. By Source of Infection 18.3.5. By Route of Administration 18.3.6. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Xellia Pharmaceuticals Ltd. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Pfizer 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Glenmark Pharmaceuticals Ltd. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Fresenius Medical Care 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. CorMedix 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. TauroPhar GmbH 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Geistlich Pharma 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Citus Pharmaceuticals 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. AstraZeneca Pharma India Ltd. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Merck Sharp & Dohme Corp 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Pathogenesis, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Source of Infection, 2018 to 2033 Table 5: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 6: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 9: North America Market Value (US$ Million) Forecast by Pathogenesis, 2018 to 2033 Table 10: North America Market Value (US$ Million) Forecast by Source of Infection, 2018 to 2033 Table 11: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 12: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 15: Latin America Market Value (US$ Million) Forecast by Pathogenesis, 2018 to 2033 Table 16: Latin America Market Value (US$ Million) Forecast by Source of Infection, 2018 to 2033 Table 17: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 18: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 19: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 20: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 21: Europe Market Value (US$ Million) Forecast by Pathogenesis, 2018 to 2033 Table 22: Europe Market Value (US$ Million) Forecast by Source of Infection, 2018 to 2033 Table 23: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 24: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 25: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: South Asia & Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 27: South Asia & Pacific Market Value (US$ Million) Forecast by Pathogenesis, 2018 to 2033 Table 28: South Asia & Pacific Market Value (US$ Million) Forecast by Source of Infection, 2018 to 2033 Table 29: South Asia & Pacific Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 30: South Asia & Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 31: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 33: East Asia Market Value (US$ Million) Forecast by Pathogenesis, 2018 to 2033 Table 34: East Asia Market Value (US$ Million) Forecast by Source of Infection, 2018 to 2033 Table 35: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 36: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 37: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 38: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 39: MEA Market Value (US$ Million) Forecast by Pathogenesis, 2018 to 2033 Table 40: MEA Market Value (US$ Million) Forecast by Source of Infection, 2018 to 2033 Table 41: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 42: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Pathogenesis, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Source of Infection, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 5: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 6: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 13: Global Market Value (US$ Million) Analysis by Pathogenesis, 2018 to 2033 Figure 14: Global Market Value Share (%) and BPS Analysis by Pathogenesis, 2023 to 2033 Figure 15: Global Market Y-o-Y Growth (%) Projections by Pathogenesis, 2023 to 2033 Figure 16: Global Market Value (US$ Million) Analysis by Source of Infection, 2018 to 2033 Figure 17: Global Market Value Share (%) and BPS Analysis by Source of Infection, 2023 to 2033 Figure 18: Global Market Y-o-Y Growth (%) Projections by Source of Infection, 2023 to 2033 Figure 19: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 20: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 21: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 22: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 23: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 24: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 25: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 26: Global Market Attractiveness by Pathogenesis, 2023 to 2033 Figure 27: Global Market Attractiveness by Source of Infection, 2023 to 2033 Figure 28: Global Market Attractiveness by Route of Administration, 2023 to 2033 Figure 29: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 30: Global Market Attractiveness by Region, 2023 to 2033 Figure 31: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 32: North America Market Value (US$ Million) by Pathogenesis, 2023 to 2033 Figure 33: North America Market Value (US$ Million) by Source of Infection, 2023 to 2033 Figure 34: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 35: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 36: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 37: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 38: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 39: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 40: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 41: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 42: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 43: North America Market Value (US$ Million) Analysis by Pathogenesis, 2018 to 2033 Figure 44: North America Market Value Share (%) and BPS Analysis by Pathogenesis, 2023 to 2033 Figure 45: North America Market Y-o-Y Growth (%) Projections by Pathogenesis, 2023 to 2033 Figure 46: North America Market Value (US$ Million) Analysis by Source of Infection, 2018 to 2033 Figure 47: North America Market Value Share (%) and BPS Analysis by Source of Infection, 2023 to 2033 Figure 48: North America Market Y-o-Y Growth (%) Projections by Source of Infection, 2023 to 2033 Figure 49: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 50: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 51: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 52: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 53: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 54: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 55: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 56: North America Market Attractiveness by Pathogenesis, 2023 to 2033 Figure 57: North America Market Attractiveness by Source of Infection, 2023 to 2033 Figure 58: North America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 59: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 60: North America Market Attractiveness by Country, 2023 to 2033 Figure 61: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 62: Latin America Market Value (US$ Million) by Pathogenesis, 2023 to 2033 Figure 63: Latin America Market Value (US$ Million) by Source of Infection, 2023 to 2033 Figure 64: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 65: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 66: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 67: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 68: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 69: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 70: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 71: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 72: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 73: Latin America Market Value (US$ Million) Analysis by Pathogenesis, 2018 to 2033 Figure 74: Latin America Market Value Share (%) and BPS Analysis by Pathogenesis, 2023 to 2033 Figure 75: Latin America Market Y-o-Y Growth (%) Projections by Pathogenesis, 2023 to 2033 Figure 76: Latin America Market Value (US$ Million) Analysis by Source of Infection, 2018 to 2033 Figure 77: Latin America Market Value Share (%) and BPS Analysis by Source of Infection, 2023 to 2033 Figure 78: Latin America Market Y-o-Y Growth (%) Projections by Source of Infection, 2023 to 2033 Figure 79: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 80: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 81: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 82: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 83: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 84: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 85: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 86: Latin America Market Attractiveness by Pathogenesis, 2023 to 2033 Figure 87: Latin America Market Attractiveness by Source of Infection, 2023 to 2033 Figure 88: Latin America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 89: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 90: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 91: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 92: Europe Market Value (US$ Million) by Pathogenesis, 2023 to 2033 Figure 93: Europe Market Value (US$ Million) by Source of Infection, 2023 to 2033 Figure 94: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 95: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 96: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 97: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 98: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 99: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 100: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 101: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 102: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 103: Europe Market Value (US$ Million) Analysis by Pathogenesis, 2018 to 2033 Figure 104: Europe Market Value Share (%) and BPS Analysis by Pathogenesis, 2023 to 2033 Figure 105: Europe Market Y-o-Y Growth (%) Projections by Pathogenesis, 2023 to 2033 Figure 106: Europe Market Value (US$ Million) Analysis by Source of Infection, 2018 to 2033 Figure 107: Europe Market Value Share (%) and BPS Analysis by Source of Infection, 2023 to 2033 Figure 108: Europe Market Y-o-Y Growth (%) Projections by Source of Infection, 2023 to 2033 Figure 109: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 110: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 111: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 112: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 113: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 114: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 115: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 116: Europe Market Attractiveness by Pathogenesis, 2023 to 2033 Figure 117: Europe Market Attractiveness by Source of Infection, 2023 to 2033 Figure 118: Europe Market Attractiveness by Route of Administration, 2023 to 2033 Figure 119: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 120: Europe Market Attractiveness by Country, 2023 to 2033 Figure 121: South Asia & Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 122: South Asia & Pacific Market Value (US$ Million) by Pathogenesis, 2023 to 2033 Figure 123: South Asia & Pacific Market Value (US$ Million) by Source of Infection, 2023 to 2033 Figure 124: South Asia & Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 125: South Asia & Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 126: South Asia & Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 127: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 128: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 129: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 130: South Asia & Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 131: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 132: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 133: South Asia & Pacific Market Value (US$ Million) Analysis by Pathogenesis, 2018 to 2033 Figure 134: South Asia & Pacific Market Value Share (%) and BPS Analysis by Pathogenesis, 2023 to 2033 Figure 135: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Pathogenesis, 2023 to 2033 Figure 136: South Asia & Pacific Market Value (US$ Million) Analysis by Source of Infection, 2018 to 2033 Figure 137: South Asia & Pacific Market Value Share (%) and BPS Analysis by Source of Infection, 2023 to 2033 Figure 138: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Source of Infection, 2023 to 2033 Figure 139: South Asia & Pacific Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 140: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 141: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 142: South Asia & Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 143: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 144: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 145: South Asia & Pacific Market Attractiveness by Drug Class, 2023 to 2033 Figure 146: South Asia & Pacific Market Attractiveness by Pathogenesis, 2023 to 2033 Figure 147: South Asia & Pacific Market Attractiveness by Source of Infection, 2023 to 2033 Figure 148: South Asia & Pacific Market Attractiveness by Route of Administration, 2023 to 2033 Figure 149: South Asia & Pacific Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 150: South Asia & Pacific Market Attractiveness by Country, 2023 to 2033 Figure 151: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 152: East Asia Market Value (US$ Million) by Pathogenesis, 2023 to 2033 Figure 153: East Asia Market Value (US$ Million) by Source of Infection, 2023 to 2033 Figure 154: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 155: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 156: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 157: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 158: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 159: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 160: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 161: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 162: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 163: East Asia Market Value (US$ Million) Analysis by Pathogenesis, 2018 to 2033 Figure 164: East Asia Market Value Share (%) and BPS Analysis by Pathogenesis, 2023 to 2033 Figure 165: East Asia Market Y-o-Y Growth (%) Projections by Pathogenesis, 2023 to 2033 Figure 166: East Asia Market Value (US$ Million) Analysis by Source of Infection, 2018 to 2033 Figure 167: East Asia Market Value Share (%) and BPS Analysis by Source of Infection, 2023 to 2033 Figure 168: East Asia Market Y-o-Y Growth (%) Projections by Source of Infection, 2023 to 2033 Figure 169: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 170: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 171: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 172: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 173: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 174: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 175: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 176: East Asia Market Attractiveness by Pathogenesis, 2023 to 2033 Figure 177: East Asia Market Attractiveness by Source of Infection, 2023 to 2033 Figure 178: East Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 179: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 180: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 181: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 182: MEA Market Value (US$ Million) by Pathogenesis, 2023 to 2033 Figure 183: MEA Market Value (US$ Million) by Source of Infection, 2023 to 2033 Figure 184: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 185: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 186: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 187: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 188: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 189: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 190: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 191: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 192: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 193: MEA Market Value (US$ Million) Analysis by Pathogenesis, 2018 to 2033 Figure 194: MEA Market Value Share (%) and BPS Analysis by Pathogenesis, 2023 to 2033 Figure 195: MEA Market Y-o-Y Growth (%) Projections by Pathogenesis, 2023 to 2033 Figure 196: MEA Market Value (US$ Million) Analysis by Source of Infection, 2018 to 2033 Figure 197: MEA Market Value Share (%) and BPS Analysis by Source of Infection, 2023 to 2033 Figure 198: MEA Market Y-o-Y Growth (%) Projections by Source of Infection, 2023 to 2033 Figure 199: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 200: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 201: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 202: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 203: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 204: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 205: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 206: MEA Market Attractiveness by Pathogenesis, 2023 to 2033 Figure 207: MEA Market Attractiveness by Source of Infection, 2023 to 2033 Figure 208: MEA Market Attractiveness by Route of Administration, 2023 to 2033 Figure 209: MEA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 210: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
